Table 1 Characteristics of studies included
Reference | Study type | Period of observation | Country | Pituitary suppression | Population | Intervention | Comparison | Results |
|---|---|---|---|---|---|---|---|---|
Humaidan et al. 2004 [20] | RCT subgroup analysis | November 2001 to October 2002 | Denmark (single-centre) | GnRH agonist long Buserelin 0.5 mg /day | N = 39 Age 35–40 years | Group A1 N = 21 r-hFSH +r-hLH r-hLH started at stimulation day 8 r-hLH dosage r-hFSH r-hLH ratio 2:1 | Group B1 N = 18 r-hFSH | Significantly higher implantation rate in r-hLH supplemented group |
RCT subgroup analysis | n.a | USA (multi-centre) | GnRH agonist long Leuprolide 0.5 mg/day | N = 121 Age 35–40 years | Group A N = 65 r-hFSH +r-hLH r-hLH started at stimulation day 6 r-hLH dosage 150 IU | Group B N = 56 r-hFSH | Higher implantation rate and clinical pregnancy rate in r-hLH supplemented group | |
Fabregues et al. 2006 [67] | RCT | November 2003 to September 2004 | Spain (single-centre) | GnRH agonist long Triptorelin 0.1 mg/day | N = 120 Age 35–42 years | Group A N = 60 r-hFSH + r-hLH r-hLH started at stimulation day 6 r-hLH dosage 150 IU | Group B N = 60 r-hFSH | Significantly lower number of oocytes retrieved and MII oocytes in r-hLH supplemented group Comparable implantation rate and pregnancy rates between groups |
Barrenetxea et al. 2008 [70] | RCT | January to June 2005 | Spain (single-centre) | GnRH agonist short Leuprolide 0.5 mg | N = 84 Age ≥ 40 years | Group A N = 42 r-hFSH + r-hLH r-hLH started at stimulation day 7 r-hLH dosage 150 IU | Group B N = 42 r-hFSH | Comparable implantation rate, pregnancy rates and number of oocytes retrieved between groups |
N. Andersen et al. 2008 [65] | RCT subgroup analysis | August 2003 to November 2004 | Denmark Sweden Norway Finland (multi-centre) | GnRH agonist long Nafarelin 200 μg twice a day | N = 100 Age 35–40 years | Group A N = 49 r-hFSH +r-hLH r-hLH started at stimulation day 6 r-hLH dosage 150 IU | Group B N = 51 r-hFSH | Comparable clinical pregnancy rate, implantation rate and number of oocytes retrieved between groups |
Matorras et al. 2009 [64] | RCT | January 2005 to November 2006 | Spain (single-centre) | GnRH agonist long Triptorelin 0.1 mg/day | N = 131 Age 35–39 years | Group B N = 63 r-hFSH + r-hLH r-hLH started at stimulation day 6 r-hLH dosage 150 IU | Group A N = 68 r-hFSH | Significantly higher implantation rate, live birth rate in r-hLH supplemented group. Higher clinical pregnancy rate in r-hLH supplemented group |
Bosch et al. 2011 [9] | RCT | January 2005 to December 2007 | Spain (single-centre) | GnRH antagonist Cetrorelix 0.25 mg/day OC during the cycle before stimulation | N = 292 Age 36–39 years | Group A N = 150 r-hFSH + r-hLH r-hLH dosage 75 IU r-hLH started at stimulation day 1 | Group B N = 142 r-hFSH | Significantly lower number of oocytes retrieved in r-hLH supplemented group Significantly higher implantation rate in r-hLH supplemented group Higher clinical pregnancy rates in r-hLH supplemented group |
Fabregues et al. 2011 [68] | RCT | January 2007 to February 2008 | Spain (single-centre) | GnRH agonist long Triptorelin 0.1 mg /day | N = 187 Age 35–41 years | Group A1 N = 62 r-hFSH + r-hLH Group A2 n = 63 r-hFSH + r-hLH r-hLH started at stimulation day 6 in A1 and A2 Group A1 r-hLH dosage 37.5 IU Group A2 r-hLH dosage 75 IU | Group B N = 62 r-hFSH | Significantly lower number of oocytes retrieved and MII oocytes in r-hLH supplemented group Comparable implantation rate and pregnancy rates between groups |
Konig et al. 2013 [36] | RCT | January 2004 to September 2010 | Netherlands (multi-centre) | GnRH antagonist Cetrorelix 0.25 mg/day | N = 253 Age 35–43 years | Group A N = 125 r-hFSH + r-hLH r-hLH started at stimulation day 6 r-hLH dosage 150 IU | Group B N = 128 r-hFSH | Comparable clinical pregnancy rate, implantation rate and n oocytes retrieved between groups |
Vuong et al. 2015 [37] | RCT | October 2012 to June 2014 | Vietnam (single-centre) | GnRH antagonist Cetrorelix | N = 240 Age ≥ 35 years | Group A N = 120 r-hFSH + r-hLH r-hLH started at stimulation day 6 r-hLH dosage 75 IU | Group B N = 120 r-hFSH | Comparable clinical pregnancy rate, implantation rate and number of oocytes retrieved between groups |
Younis et al. 2016 [66] | RCT | April 2010 to April 2013 | Israel (single-centre) | GnRH antagonist Cetrorelix 0.25 mg/day | N = 62 Age 35–44 years | Group A N = 32 r-hFSH +r-hLH r-hLH started with antagonist r-hLH dosage r-hFSH r-hLH ratio 2:1 | Group B N = 30 r-hFSH | Comparable clinical pregnancy rate, implantation rate and number of oocytes retrieved between groups |
Humaidan et al. 2017 [71] | RCT | January 2014 and February 2015 | Denmark (multi-centre) | GnRH agonist long Triptorelin acetate 0.1 mg | N = 821 Age 35–41 years BMI 18–31 kg/m2 Poor response according the Bologna criteria | Group A N = 405 r-hFSH + r-hLH r-hLH started at stimulation day 1 r-hLH dosage r-hFSH r-hLH ratio 2:1 | Group B N = 416 r-hFSH | Comparable number of oocytes retrieved |